<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Ascendis Pharma A/s — News on 6ix</title>
    <link>https://6ix.com/company/ascendis-pharma-as</link>
    <description>Latest news and press releases for Ascendis Pharma A/s on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 21 Apr 2026 20:31:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/ascendis-pharma-as" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69f4648309d83656aec1d339.webp</url>
      <title>Ascendis Pharma A/s</title>
      <link>https://6ix.com/company/ascendis-pharma-as</link>
    </image>
    <item>
      <title>Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/ascendis-announces-redemption-of-all-dollar575-million-of-outstanding-225percent-convertible-senior-notes-due-2028</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/ascendis-announces-redemption-of-all-dollar575-million-of-outstanding-225percent-convertible-senior-notes-due-2028</guid>
      <pubDate>Tue, 21 Apr 2026 20:31:00 GMT</pubDate>
      <description>COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has called all $575.0 million aggregate principal amount of its outstanding 2.25% Convertible Senior Notes due 2028 (the “notes”) (CUSIP No. 04351P AD3 / ISIN No. US04351PAD33) for redemption on May 6, 2026 (the “Redemption Date”). Ascendis’ redemption right in respect of the notes arises pursuant to Section 4.03(B) of the indenture (the “Indenture”), dated as of March 29, 2022, bet</description>
    </item>
    <item>
      <title>Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/ascendis-pharma-announces-commencement-of-trading-of-its-ordinary-shares-on-nasdaq</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/ascendis-pharma-announces-commencement-of-trading-of-its-ordinary-shares-on-nasdaq</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 GMT</pubDate>
      <description>COPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (Nasdaq), replacing the listing of American Depositary Shares (ADSs). The ordinary shares trade under the same ticker symbol “ASND” as previously used for the ADS listing. The ordinary shares trade under CUSIP number K08588103 and ISIN DK0060606333. On April 8, 2026, the Company announced plans to mandator</description>
    </item>
    <item>
      <title>Ascendis Pharma to List Ordinary Shares Directly on Nasdaq</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/ascendis-pharma-to-list-ordinary-shares-directly-on-nasdaq</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/ascendis-pharma-to-list-ordinary-shares-directly-on-nasdaq</guid>
      <pubDate>Wed, 08 Apr 2026 16:00:00 GMT</pubDate>
      <description>- Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs) - ADS holders will receive one ordinary share listed on Nasdaq for each ADS held - Simplified listing structure intended to enable enhanced depth and breadth of ownership COPENHAGEN, Denmark, April 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it plans to list its ordinary shares directly on Nasdaq, effective at the opening</description>
    </item>
    <item>
      <title>Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/ascendis-receives-orphan-drug-exclusivity-and-launches-yuviwelr-navepegritide-in-the-united-states</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/ascendis-receives-orphan-drug-exclusivity-and-launches-yuviwelr-navepegritide-in-the-united-states</guid>
      <pubDate>Mon, 06 Apr 2026 20:01:00 GMT</pubDate>
      <description>- YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses - YUVIWEL is now commercially available in the U.S. with revenue now recognized following approval of first patients and initiation of therapy COPENHAGEN, Denmark, April 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YUVIWEL (navepegritide; developed as TransCon® CNP) was granted orphan dru</description>
    </item>
    <item>
      <title>New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/new-insights-trial-of-transconr-hgh-lonapegsomatropin-in-turner-syndrome-demonstrated-comparable-efficacy-and-safety-to-daily-somatropin-at-week-52</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/new-insights-trial-of-transconr-hgh-lonapegsomatropin-in-turner-syndrome-demonstrated-comparable-efficacy-and-safety-to-daily-somatropin-at-week-52</guid>
      <pubDate>Tue, 17 Mar 2026 12:30:00 GMT</pubDate>
      <description>- Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated children - TransCon hGH showed a safety and tolerability profile comparable to daily somatropin with no occurrences of slipped capital femoral epiphysis (SCFE) COPENHAGEN, Denmark, March 17, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced positive Week 52 topline results from New InsiGHTS, its Phase 2 randomized, open-label, activ</description>
    </item>
    <item>
      <title>New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/new-two-year-data-from-pivotal-approach-trial-showing-durable-benefits-of-transconr-cnp-navepegritide-in-children-with-achondroplasia-shared-at-acmg-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/new-two-year-data-from-pivotal-approach-trial-showing-durable-benefits-of-transconr-cnp-navepegritide-in-children-with-achondroplasia-shared-at-acmg-2026</guid>
      <pubDate>Mon, 16 Mar 2026 12:00:00 GMT</pubDate>
      <description>COPENHAGEN, Denmark, March 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from its pivotal ApproaCH Trial showing that children with achondroplasia treated with once-weekly TransCon CNP (navepegritide) maintained consistent improvements in growth through Week 104, with further improvement in body proportionality during the second year of treatment. These and other results were shared in an oral presentation by Dr. Ravi Savarirayan, M.B.B.S., M.D., Murdoc</description>
    </item>
    <item>
      <title>Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/ascendis-pharma-to-participate-in-the-td-cowen-46th-annual-health-care-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/ascendis-pharma-to-participate-in-the-td-cowen-46th-annual-health-care-conference</guid>
      <pubDate>Mon, 02 Mar 2026 13:43:00 GMT</pubDate>
      <description>COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a virtual fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time in Boston, Massachusetts. A live webcast of the presentation will be available via the Investors &amp; News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay wil</description>
    </item>
    <item>
      <title>FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/fda-approves-once-weekly-yuviwelr-navepegritide-for-children-with-achondroplasia-aged-2-years-and-older</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/fda-approves-once-weekly-yuviwelr-navepegritide-for-children-with-achondroplasia-aged-2-years-and-older</guid>
      <pubDate>Fri, 27 Feb 2026 22:57:00 GMT</pubDate>
      <description>The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pediatric Disease Priority Review Voucher granted in connection with approvalAscendis to host investor conference call Monday, March 2, at 8:00 am ET COPENHAGEN, Denmark, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food &amp; Drug Administration (FDA) ha</description>
    </item>
    <item>
      <title>Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/ascendis-pharma-reports-fourth-quarter-and-full-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/ascendis-pharma-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
      <pubDate>Wed, 11 Feb 2026 21:01:00 GMT</pubDate>
      <description>Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 millionQ4 2025 operating profit of €10 million and cash flow from operating activities of €73 millionTransCon® CNP under FDA Priority Review, PDUFA action goal date of February 28, 2026Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a bu</description>
    </item>
    <item>
      <title>Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/ascendis-pharma-to-report-full-year-2025-financial-results-and-provide-business-update-on-february-11-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/ascendis-pharma-to-report-full-year-2025-financial-results-and-provide-business-update-on-february-11-2026</guid>
      <pubDate>Wed, 04 Feb 2026 21:01:00 GMT</pubDate>
      <description>COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on February 11, 2026, at 4:30 p.m. Eastern Time (ET) to discuss 2025 financial results. Those who would like to participate may access the live webcast here, or r</description>
    </item>
    <item>
      <title>Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/ascendis-pharma-provides-business-and-strategic-roadmap-update-at-44th-annual-jp-morgan-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/ascendis-pharma-provides-business-and-strategic-roadmap-update-at-44th-annual-jp-morgan-healthcare-conference</guid>
      <pubDate>Fri, 09 Jan 2026 23:01:00 GMT</pubDate>
      <description>- Rapidly transforming into a leading global biopharma companyCOPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present this update on Monday, January 12, during the 44th Annual J.P. Morgan Healthcare Conference. “With our proven TransCon® technology platform, strong R&amp;D capabilities, and a maturing commerci</description>
    </item>
    <item>
      <title>Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/week-52-coach-trial-topline-results-confirm-consistent-and-durable-treatment-benefits-in-children-with-achondroplasia-ach</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/week-52-coach-trial-topline-results-confirm-consistent-and-durable-treatment-benefits-in-children-with-achondroplasia-ach</guid>
      <pubDate>Thu, 08 Jan 2026 21:01:00 GMT</pubDate>
      <description>– Once-weekly TransCon® CNP and TransCon® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV) exceeded the 97th-percentile of average stature children – ACH height Z-score improvements indicated a tripling of efficacy compared to TransCon CNP monotherapy – Combination therapy demonstrated benefits beyond linear growth with improvements in body proportionality and arm span, aligning with the increase in linear gr</description>
    </item>
    <item>
      <title>Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/ascendis-pharma-to-participate-in-the-44th-annual-jp-morgan-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/ascendis-pharma-to-participate-in-the-44th-annual-jp-morgan-healthcare-conference</guid>
      <pubDate>Mon, 05 Jan 2026 13:30:00 GMT</pubDate>
      <description>COPENHAGEN, Denmark, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 44th Annual J.P. Morgan Healthcare Conference and provide a business update on Monday, January 12, 2026, at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time in San Francisco, California. A live webcast of the presentation will be available via the Investors &amp; News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast</description>
    </item>
    <item>
      <title>Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/ascendis-announces-extension-of-fda-review-period-for-transcon-cnp-navepegritide-for-children-with-achondroplasia</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/ascendis-announces-extension-of-fda-review-period-for-transcon-cnp-navepegritide-for-children-with-achondroplasia</guid>
      <pubDate>Tue, 25 Nov 2025 23:15:00 GMT</pubDate>
      <description>– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026 COPENHAGEN, Denmark, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food &amp; Drug Administration (FDA) notified the Company that information submitted on November 5, 2025, related to the post-marketing requirement, in response to the FDA’s ongoing review of the New Drug Application (NDA) for TransCon CNP (navepegritide) for children with achondroplasi</description>
    </item>
    <item>
      <title>Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/results-of-pivotal-approach-trial-of-transconr-cnp-navepegritide-in-children-with-achondroplasia-published-in-jama-pediatrics</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/results-of-pivotal-approach-trial-of-transconr-cnp-navepegritide-in-children-with-achondroplasia-published-in-jama-pediatrics</guid>
      <pubDate>Mon, 17 Nov 2025 21:01:00 GMT</pubDate>
      <description>COPENHAGEN, Denmark, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Trial of investigational once-weekly TransCon® CNP (navepegritide) in children with achondroplasia have been published in JAMA Pediatrics, a journal of the American Medical Association. In the publication, titled “Once-Weekly Navepegritide in Children with Achondroplasia: The ApproaCH Randomized Clinic</description>
    </item>
    <item>
      <title>Ascendis Pharma Reports Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/ascendis-pharma-reports-third-quarter-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/ascendis-pharma-reports-third-quarter-2025-financial-results</guid>
      <pubDate>Wed, 12 Nov 2025 21:01:00 GMT</pubDate>
      <description>– Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA® – Q3 2025 operating profit of €11.0 million – TransCon® CNP (navepegritide) under FDA Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025 – Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the third quarter ended September 30, 2025, and provided a bus</description>
    </item>
    <item>
      <title>New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/new-pooled-3-year-analysis-confirms-sustained-clinically-meaningful-improvements-in-renal-function-for-transconr-pth-palopegteriparatide-treated-adults-with-hypoparathyroidism</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/new-pooled-3-year-analysis-confirms-sustained-clinically-meaningful-improvements-in-renal-function-for-transconr-pth-palopegteriparatide-treated-adults-with-hypoparathyroidism</guid>
      <pubDate>Fri, 07 Nov 2025 13:30:00 GMT</pubDate>
      <description>COPENHAGEN, Denmark, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal function in adults with hypoparathyroidism treated with TransCon PTH (palopegteriparatide) through Year 3 of the Company’s Phase 2 PaTH Forward and Phase 3 PaTHway trials. The data, which confirm results for each individual trial presented at major endocrinology meetings earlier this year, were shared</description>
    </item>
    <item>
      <title>Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/ascendis-pharma-to-report-third-quarter-2025-financial-results-and-provide-business-update-on-november-12-2025</guid>
      <pubDate>Wed, 05 Nov 2025 21:01:00 GMT</pubDate>
      <description>COPENHAGEN, Denmark, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report third quarter 2025 financial results and provide a business update on Wednesday, November 12, 2025, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on November 12, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its third quarter 2025 financial results. Those who would like to participate may access the l</description>
    </item>
    <item>
      <title>3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transconr-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transconr-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025</guid>
      <pubDate>Mon, 03 Nov 2025 21:01:00 GMT</pubDate>
      <description>COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued normalization of urine calcium handling, and continued safety and efficacy in adults with hypoparathyroidism treated with TransCon PTH (palopegteriparatide) through Year 3 of the Phase 2 PaTH Forward and Phase 3 PaTHway trials will be shared during Kidney Week 2025, the annual meeting of the American Society for Nephro</description>
    </item>
    <item>
      <title>Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia</title>
      <link>https://6ix.com/company/ascendis-pharma-as/news/ascendis-submits-marketing-authorisation-application-to-the-european-medicines-agency-for-transconr-cnp-for-treatment-of-children-with-achondroplasia</link>
      <guid isPermaLink="true">https://6ix.com/company/ascendis-pharma-as/news/ascendis-submits-marketing-authorisation-application-to-the-european-medicines-agency-for-transconr-cnp-for-treatment-of-children-with-achondroplasia</guid>
      <pubDate>Wed, 08 Oct 2025 20:01:00 GMT</pubDate>
      <description>COPENHAGEN, Denmark, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon CNP (navepegritide) as a treatment for children with achondroplasia, a rare genetic condition that causes skeletal dysplasia and, for many affected individuals, significant health, physical functioning, and quality of life impacts. TransCon CNP is an investigational prodrug of C-t</description>
    </item>
  </channel>
</rss>